Canada’s Aurora Cannabis Inc.’s wholly owned subsidiary, MedReleaf Australia, has entered into a distribution partnership with the wholesale distribution arm of local firm Montu Australia, Leafio.
Through the arrangement, Aurora medical cannabis products will be distributed through Leafio’s nationwide supply chain, which is comprised of 4,000 pharmacies. Aurora says the strategic partnership will expand patient access to its products across Australia, while supporting healthcare professionals with educational resources.
Commenting on the deal, General Manager of Leafio Nicole Le Maistre said:
“Together, Leafio and Aurora can reach more Australian patients through trusted medical channels, bolstering access to world-class products and expertise. This partnership will deliver meaningful benefits to the region’s medical cannabis industry, from enhanced research and product innovation to trusted education and improved patient outcomes.”
Aurora Cannabis built its first facility in Western Canada under MMPR guidelines to meet Health Canada standards back in 2013 and was granted a federal license (Canada) to cultivate and sell medical cannabis in 2015. The firm sold its first gram of medical cannabis as a licensed producer the following year. In 2024, Aurora completed the acquisition of MedReleaf Australia; which began operations in 2018.
Leafio was established in 2023, is headquartered in Victoria and has warehouses in New South Wales, Victoria and Queensland. The company says it offers 1,000+ cannabis products from more than 100 brands. Parent company Montu Australia, founded in 2019 and headquartered in Melbourne, was named the fastest growing tech company in Australia (Deloitte Technology Fast 50) in both 2022 and 2023 after achieving revenue growth of more than 20,700% and 9,600% respectively.
In other news from Aurora, the firm recently announced its financial and operational results for the second quarter period ending September 30, 2025. The company says it achieved record net revenue for global medical cannabis, with a 15% year-over-year increase. Adjusted net income was $7.1 million for the three months ended September 30, 2025 compared to $3.0 million for the three months ended September 30, 2024.
“Looking ahead, we intend to deliver continued strong results for our shareholders supported by a sizable cash balance and debt-free cannabis business,” said Aurora Executive Chairman and Chief Executive Officer, Miguel Martin.
